Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-08-21

Schrodinger, Inc.

Schrödinger sells physics-based molecular design software and uses the same platform in partnered and proprietary drug discovery programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From molecular tools to workflow ownership

The key question is whether this business becomes a deeper operating layer in pharma discovery rather than just a better modeling toolkit. If hosted contracts, agentic workflows, and selective collaboration monetization compound together, the stock can deliver a solid multi-year rerating without needing a single blockbuster asset outcome.

Analysis

Thesis

Schrödinger’s best 5-year path is not a single drug win but a business-model upgrade: if hosted delivery, workflow embedding, and Bunsen turn its simulation stack into a program-level operating layer for pharma, rising discovery throughput can convert into cleaner recurring revenue, selective milestone upside, and a meaningful rerating.

Last Economy Alignment

AI should expand in-silico discovery demand, and Schrödinger owns validated workflow and trust layers that can capture part of that growth. The main risk is that internal pharma stacks or outside agents keep the interface and compress pricing.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.2x (from 5 most recent analyses)

Reasoning

The upside case is a cleaner and broader software story, not a moonshot biotech case. Hosted contracts make demand more durable, Bunsen can widen the user base beyond specialist computational chemists, and collaboration revenue adds non-linear upside without needing the company to fully self-fund late-stage development. The rerating is real but capped because investors still need proof that AI raises paid workflow control rather than just usage.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is value capture, not scientific relevance. Schrödinger likely remains useful in AI-era drug discovery, but the equity case weakens if hosted delivery mainly changes accounting, if Bunsen lifts usage without lifting paid control, or if large pharma internal stacks own the workflow and relegate Schrödinger to a component supplier.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Second-quarter results and the August 12, 2026 call improved confidence that software demand is real even though reported revenue is still distorted by the hosted transition.
The Bristol Myers Squibb deployment moved Bunsen from concept to a credible enterprise proof point, but it is still too early to treat it as a fully monetized growth engine.
No material fundamental disclosure arrived after mid-August beyond a small inducement equity grant, so the setup remains dominated by the next ACV proof gate rather than new news.

Forecast update

The upside is now driven more by execution against a clearer software demand signal and less by assuming a large terminal multiple expansion.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.44

They own a trusted workspace and simulation engine that pharma teams already use, so cheaper AI can send more discovery work through their system. The danger is that big drug companies let their own agents sit on top and turn Schrödinger into a back-end tool instead of the control point.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$21.43

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research